

AMENDMENTS

In the Claims

Please amend claims 1, 10 and 22 as follows:

1. (currently amended) A method for treating an acute medical condition in a subject with a lipophilic agent, ~~[comprising]~~ consisting of:

providing the lipophilic agent in an oil formulation in the presence of benzyl alcohol, and

administering the formulation subcutaneously (i) to provide a peak plasma concentration of the lipophilic agent within 4 hours after the subcutaneous administration; and (ii) to achieve sustained delivery.

2. (original) The method according to claim 1, wherein the lipophilic molecule is a polycyclic phenolic compound.

3. (original) The method according to claim 2, wherein the polycyclic phenolic compound is a steroid.

Claim 4. (withdrawn)

5. (original) The method according to claim 1, wherein the lipophilic molecule is a benzo-diazapine.

6. (original) The method according to claim 5, wherein the benzodiazapine is diazepam.

7. (original) The method according to claim 1, wherein the oil is one or more vegetable oils.

~~8. (original) The method according to claim 7, wherein the vegetable oil is selected from the group consisting of corn, sesame, cottonseed, soybean, poppy seed, castor, olive, canola, rapeseed, peanut, sunflower and mixtures thereof.~~

9. (original) A method according to claim 1, wherein the medical condition is an ischemic condition or trauma.

10. (currently amended) A method according to claim 9, wherein the ischemic condition or trauma is selected from: a stroke, ~~[subarachnoid]~~ subarachnoid hemorrhage, cerebrovascular injury, vasospasm, head injury, myocardial infarction and angina.

11. (original) A method according to claim 1, wherein the medical condition is an epileptic seizure.

Claims 12 – 21. (withdrawn)

22. A method of treating an acute medical condition in a subject with a non-estrogenic lipophilic agent, [~~comprising~~] consisting of:

providing the non-estrogenic lipophilic agent in an oil formulation, and administering the formulation subcutaneously (i) to provide a peak plasma concentration of the lipophilic agent within 4 hours after the subcutaneous administration; and (ii) to achieve sustained delivery.

23. A method according to claim 22, wherein the lipophilic agent is a polycyclic compound with a terminal phenol group other than estrogen.

24. A method according to claim 22, wherein the lipophilic compound is benzodiazepine.

25. A method according to claim 24, wherein the benzodiazepine is diazepam.
